Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICM20 Alone and in Combination With Benznidazole in Chagas Disease
NCT05523596Phase 1Completed
- Sponsor
- IC-MedTech
- Start
- Aug 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ICM20 in Chagas disease (4 arms), sponsored by IC-MedTech. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 90 days. Started Aug 2023; status: completed.
02
Drugs
ICM20
03
Conditions
Chagas disease
Beyond the preview
Go deeper on NCT05523596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05523596.